Bruceantinol works as a CDK2/4/6 inhibitor to inhibit the growth of breast cancer cells

Bruceantinol (BOL), isolated from the dried fruit of the Brucea javanica (L.) Merr., exhibits cytotoxic effects on breast Cancer cells. However, the underlying mechanism remains to be fully addressed. In this paper, the MCF-7 and MDA-MB-231 human breast Cancer cell lines were used as experimental models to uncover how BOL inhibits breast Cancer cell growth. The effects of BOL on cell growth, proliferation, the cell cycle, and Apoptosis were investigated using the MTT assays, EdU incorporation assays, and flow cytometry, respectively. Bioinformatics techniques were applied to predict the key targets of BOL in breast Cancer. Subsequent validation of these targets and the anti-breast Cancer mechanism of BOL was conducted through Western blotting, RT-PCR, siRNA transfection, and molecular docking analysis. The results demonstrated that BOL dose- and time-dependently reduced the growth of both cell lines, impeded cell proliferation, disrupted the cell cycle, and induced necrosis in MCF-7 cells and Apoptosis in MDA-MB-231 cells. Furthermore, CDK2/4/6 were identified as BOL targets, and their knockdown reduced cell sensitivity to BOL. BOL was found to potentially bind with CDK2/4/6 to facilitate protein degradation through the Proteasome pathway. Additionally, BOL activated ERK in MDA-MB-231 cells, and this activation was required for BOL's functions in these cells. Collectively, BOL may act as an inhibitor of CDK2/4/6 to exert anti-breast Cancer effects. Its effects on cell growth and CDK2/4/6 expression may also depend on ERK activation in HRs^-HER2^- breast Cancer cells. These results suggest the potential of using BOL for treating breast Cancer.

Breast cancer; Bruceantinol; Cell cycle; Cyclin-dependent kinases (CDKs); ERK1/2.